Evolve Telemedicine vs Keeps
A detailed head-to-head comparison of Evolve Telemedicine and Keeps — pricing, peptides, consultation models, and patient reviews.
At a Glance
RatingNo reviews
Starting PriceN/A
Peptides2
ConsultationHybrid
Lab TestingNo
Shipping3-5 business days
Pros
- Competitive pricing relative to larger, brand-name telehealth platforms (based on publicly available positioning)
- Broad service menu covering weight management, hormones, and sexual health in one platform
- Digital-first model means no travel or in-person visits required
- May offer a faster or simpler sign-up process than more comprehensive platforms
Cons
- Limited public information about the platform
- The compounded GLP-1 regulatory environment creates meaningful uncertainty for any platform that relied on compounded semaglutide or tirzepatide pathways
- Smaller platforms carry more risk of service disruptions, formulary changes, or operational issues than well-capitalized incumbents
- No physical clinic locations
- Patient reviews and independent third-party coverage are sparse compared to larger competitors, making reputation assessment harder
RatingNo reviews
Starting PriceN/A
Peptides1
ConsultationHybrid
Lab TestingNo
Shipping3-5 business days
Pros
- Familiar men's health brand
- Bundled convenience
- Async-first workflow
- Streamlined onboarding
Cons
- GLP-1 program is newer
- Compounding regulatory uncertainty
- Men only
- Limited ongoing clinical support
Pros & Cons
Peptide Pricing Comparison
| Peptide | Evolve Telemedicine | Keeps |
|---|---|---|
| Semaglutide | Price unavailable | Price unavailable |
| Tirzepatide | Price unavailable | Not offered |
Frequently Asked Questions
Is Evolve Telemedicine or Keeps better?
Evolve Telemedicine offers 2 peptides and hybrid consultations. Keeps offers 1 peptide and hybrid consultations. The best choice depends on which peptides you need, your budget, and preferred consultation model.
Which is cheaper, Evolve Telemedicine or Keeps?
See the pricing table above for a detailed comparison.